Enhancing Mesenchymal Stem Cell Efficacy For Cell Therapy
- Technology Application
- A method for producing scalable human MSCsfrom different tissue sources for use in treating inflammatory diseases such asOA, ARDS, GvHD, inflammation in neurodegenerative diseases (e.g. Alzheimer,Parkinson’s), spinocerebellarataxia, liver diseases (acute and chronic), sepsis, diabetes, spinal cordinjury, kidney diseases (acute and chronic ) etc.A method for producing scalable human MSCsfrom different tissue sources for use in treating solid and hematologicalmalignancies with or without genetic modificationA method producing scalable canine andequine MSCs from different tissue sources for use in treating musculoskeletaldisorders in dogs and horses
- Detailed Technology Description
- A novel method to manufacturehigh quality cost effective mesenchymal stem cells for clinical applications
- *Abstract
-
A transiently physical culture condition inthe presence of a proprietary cytokine/small molecule cocktail activates MSCsthat have already been expanded to be more anti-inflammatory, anti-tumor andimmunomodulatory. This method can be applied to MCB/WCBs to prepare activatedcryopreserved MSC product cell banks which retain their activity, post thaw.This method can also be applied post-thaw to cryopreserved MSC cell banks.
High potency stem cell therapeuticapplications create ample opportunities for a variety of applications inregenerative medicine. Researchers at University Health Network have developeda method which alters critical culture conditions under specific and proprietarysequences thereby enabling anti-inflammatory, anti-tumor, and immunomodulatoryproperties in MSCs. Enhancement in bone marrow- and umbilical cord tissue-MSCsby this proprietary method has been evaluated in vitro by measuring anti-inflammatory protein tumornecrosis factor inducible gene 6 (TSG-6) expression, inhibition of CD4+ Thelper (TH) proliferation and in vivo by subsidence of LPS (in paw edema) andzymosan induced (in peritoneum) inflammation.
- *Principal Investigator
-
Dr. SowmyaViswanathan,University Health Network (lead researcher)
- *Publications
- S. Bhatt,A. Gómez-Aristizábal, S. Viswanathan. Culture engineered mesenchymalstromal cells with enhanced anti-inflammatory and anti-angiogenic propertiesare therapeutically attractive for multiple indications. Cytotherapy 2017 19(5).
- Country/Region
- USA
